drugset / Trial / NCT00383578

Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes

NCT00383578

Phase 3 Completed 335 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes

Timeline

Start
2006-09
Primary completion
2008-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 1500 mg
Subject Vildagliptin Other / unclassified 100 mg